CL2019003720A1 - Aplicación de totarol y composición farmacéutica que contiene totarol. - Google Patents

Aplicación de totarol y composición farmacéutica que contiene totarol.

Info

Publication number
CL2019003720A1
CL2019003720A1 CL2019003720A CL2019003720A CL2019003720A1 CL 2019003720 A1 CL2019003720 A1 CL 2019003720A1 CL 2019003720 A CL2019003720 A CL 2019003720A CL 2019003720 A CL2019003720 A CL 2019003720A CL 2019003720 A1 CL2019003720 A1 CL 2019003720A1
Authority
CL
Chile
Prior art keywords
totarol
treatment
inflammations
weight
pharmaceutical composition
Prior art date
Application number
CL2019003720A
Other languages
English (en)
Inventor
Mariusz Cieciara
Artur Wrzosek
Original Assignee
Emergopharm Sp Z O O Sp K
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Emergopharm Sp Z O O Sp K filed Critical Emergopharm Sp Z O O Sp K
Publication of CL2019003720A1 publication Critical patent/CL2019003720A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A61K9/0036—Devices retained in the vagina or cervix for a prolonged period, e.g. intravaginal rings, medicated tampons, medicated diaphragms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Inorganic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Gynecology & Obstetrics (AREA)
  • Endocrinology (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Urology & Nephrology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

LA INVENCIÓN SE RELACIONA CON LA APLICACIÓN DE TOTAROL PARA LA PRODUCCIÓN DE UNA PREPARACIÓN PARA EL TRATAMIENTO DE LAS INFLAMACIONES DE LA MEMBRANA MUCOSA VAGINAL DE ORIGEN BACTERIANO, PARA EL ALIVIO DE LOS SÍNTOMAS EN DICHO TRATAMIENTO Y PARA LA PROFILAXIS Y PREVENCIÓN DE RECAÍDAS DE TALES INFLAMACIONES. LA INVENCIÓN TAMBIÉN INCLUYE UNA COMPOSICIÓN FARMACÉUTICA PARA EL TRATAMIENTO DE INFLAMACIONES DE LA MEMBRANA MUCOSA VAGINAL DE ORIGEN BACTERIANO, PARA EL ALIVIO DE LOS SÍNTOMAS EN DICHO TRATAMIENTO Y PARA LA PROFILAXIS Y PREVENCIÓN DE RECAÍDAS DE TALES INFLAMACIONES, QUE CONTIENE DE 75 A 95 PARTES EN PESO DE UN DERIVADO DE CELULOSA, PREFERIBLEMENTE METILCELULOSA, DE 0,5 A 5 PARTES EN PESO DE ÁCIDO LÁCTICO, DE 0,5 A 5 PARTES EN PESO DE UN POLÍMERO BÁSICO, EN DONDE LA RELACIÓN ESTEQUIOMÉTRICA DE ÁCIDO LÁCTICO AL POLÍMERO BÁSICO ESTÁ COMPRENDIDA EN EL INTERVALO DE 1:1 A 8:1, Y COMPRENDE TOTAROL EN UNA CANTIDAD DE 0,001 A 5 PARTES EN PESO COMO EL INGREDIENTE ACTIVO.
CL2019003720A 2017-07-06 2019-12-18 Aplicación de totarol y composición farmacéutica que contiene totarol. CL2019003720A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PL422140A PL236429B1 (pl) 2017-07-06 2017-07-06 Zastosowanie totarolu do wytwarzania preparatu do leczenia bakteryjnego zakażenia pochwy i kompozycja farmaceutyczna do zastosowania w leczeniu stanów zapalnych pochwy o podłożu bakteryjnym

Publications (1)

Publication Number Publication Date
CL2019003720A1 true CL2019003720A1 (es) 2020-05-22

Family

ID=63518002

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2019003720A CL2019003720A1 (es) 2017-07-06 2019-12-18 Aplicación de totarol y composición farmacéutica que contiene totarol.

Country Status (19)

Country Link
US (1) US11534412B2 (es)
EP (1) EP3648751B1 (es)
KR (1) KR20200024921A (es)
BR (1) BR112019027839A2 (es)
CA (1) CA3066602C (es)
CL (1) CL2019003720A1 (es)
DK (1) DK3648751T3 (es)
ES (1) ES2929646T3 (es)
HR (1) HRP20221338T1 (es)
HU (1) HUE060300T2 (es)
IL (1) IL271875B2 (es)
LT (1) LT3648751T (es)
MA (2) MA50979B1 (es)
PL (1) PL236429B1 (es)
PT (1) PT3648751T (es)
RS (1) RS63728B1 (es)
SI (1) SI3648751T1 (es)
UA (1) UA126031C2 (es)
WO (1) WO2019009739A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN114948891A (zh) * 2021-06-07 2022-08-30 南通联亚药业股份有限公司 药物组合物

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL201869A1 (pl) 1977-10-29 1979-05-21 Inst Przemyslu Organiczego Sposob wytwarzania masy kablowej odpornej na dzialanie termitow
PL107491B1 (pl) 1977-10-29 1980-02-29 Przemyslowy Instytut Automatyk Czujnik dwustrunowy do pomiaru malych przesuniec
JP2700071B2 (ja) 1988-06-10 1998-01-19 株式会社資生堂 抗菌剤及びそれを用いた皮膚外用剤、口腔用組成物
PL166898B1 (pl) 1992-02-13 1995-06-30 Akad Medyczna Sposób wytwarzania kompleksu metylocelulozy z kwasem mlekowym
US6534548B1 (en) * 2001-10-02 2003-03-18 Kimberly-Clark Worldwide, Inc. Isoprenoid compositions for the inhibition of exoprotein production from gram positive bacteria
PL194437B1 (pl) 2002-06-05 2007-05-31 Akademia Medyczna Im Piastow S Sposób wytwarzania kompleksu na bazie kwasu mlekowego
NZ530834A (en) 2004-01-28 2007-06-29 Owen John Catchpole Near-critical extraction of totarol and/or a product containing totarol
US20090312279A1 (en) * 2005-12-23 2009-12-17 Sterilex Technologies, Llc Antimicrobial compositions
EP1925302A1 (en) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Dietary or pharmaceutical compositions containing tricyclic diterpenes and derivatives thereof for the treatment of depression
EP1925301A1 (en) * 2006-11-24 2008-05-28 DSMIP Assets B.V. Use of tricyclic diterpenes and their derivatives for the treatment, co-treatment or prevention of inflammatory disorders and/or joint disorders
JP5471335B2 (ja) * 2009-11-17 2014-04-16 ライオン株式会社 口腔バイオフィルム殺菌剤
CN103974617B (zh) * 2011-12-15 2015-11-25 高露洁-棕榄公司 百里酚和桃拓酚抗菌组合物
WO2014137231A2 (en) 2013-03-07 2014-09-12 T2G Biotechnology Limited Totarol extract formulations and uses thereof
DE102013108870A1 (de) * 2013-08-16 2015-02-19 Aimecs Gmbh Mittel zur Reinigung und zum Schutz von technischen Oberflächen
CN104027260A (zh) 2014-06-20 2014-09-10 广州薇美姿个人护理用品有限公司 一种含有桃柘酚的口腔护理用品
CN104688810A (zh) * 2014-12-29 2015-06-10 昆明皕凯科技有限公司 一种基于天然植物原料的抗菌组合物及其应用
CN106581687A (zh) * 2016-12-22 2017-04-26 吉林大学 以乳清蛋白为基质的桃柁酚抗菌纳米水凝胶及其制备方法

Also Published As

Publication number Publication date
RU2020104832A (ru) 2021-08-06
HUE060300T2 (hu) 2023-02-28
CA3066602A1 (en) 2019-01-10
SI3648751T1 (sl) 2023-03-31
UA126031C2 (uk) 2022-08-03
PL236429B1 (pl) 2021-01-11
US11534412B2 (en) 2022-12-27
CA3066602C (en) 2024-01-02
PT3648751T (pt) 2022-10-20
MA50979A (fr) 2020-10-14
MA50980A (fr) 2020-10-14
RS63728B1 (sr) 2022-12-30
WO2019009739A1 (en) 2019-01-10
MA50979B1 (fr) 2022-11-30
EP3648751B1 (en) 2022-09-28
HRP20221338T1 (hr) 2022-12-23
WO2019009739A4 (en) 2019-02-28
ES2929646T3 (es) 2022-12-01
DK3648751T3 (da) 2022-11-21
IL271875A (en) 2020-02-27
LT3648751T (lt) 2022-12-12
EP3648751A1 (en) 2020-05-13
BR112019027839A2 (pt) 2020-07-07
IL271875B2 (en) 2023-02-01
US20200289429A1 (en) 2020-09-17
IL271875B (en) 2022-10-01
KR20200024921A (ko) 2020-03-09
RU2020104832A3 (es) 2021-10-08
PL422140A1 (pl) 2019-01-14

Similar Documents

Publication Publication Date Title
BR112012023421A2 (pt) composição farmacêutica para tratamento de aumento de pressão intraocular
CO6571900A2 (es) Composiciones famaceúticas del compuesto espiro-oxindol para adminsitración tópica y sus usos como agentes terapeúticos
CO6710926A2 (es) Compuestos de n-heteroarilo
BR112017023764A2 (pt) derivados de ciclohexano substituído por amido
SV2018005750A (es) Derivados de compuestos de indol sustituidos como inhibidores de la replicacion virica del dengue
EA201690102A1 (ru) Фармацевтическая композиция, содержащая диметилфумарат, для введения в низкой суточной дозе
CU20130036A7 (es) Triazina-oxidazoles
CR20140113A (es) Imidazopiridazinas sustituidas con amino
AR084932A1 (es) Composicion oftalmica que comprende un androgeno y su uso para la fabricacion de un medicamento util para el tratamiento de una enfermedad ocular resultante de una deficiencia androgenica
CO6680667A2 (es) Derivados ester de ácido borónico cíclico y sus usos terapéuticos
EA201390198A1 (ru) Гетероциклическое соединение
CL2020000747A1 (es) Formulaciones de niraparib.
CO6640327A2 (es) Compuestos de pirazol como inhibidores del receptor sigma
PE20190181A1 (es) Procedimiento de preparacion de 5-fluoro-1h-pirazolopiridinas sustituidas
NI201400003A (es) Una nueva composición terapéutica que contiene apomorfina como ingrediente activo
CO2019007409A2 (es) Derivados de la pirimidin enona tricíclica para la inhibición de rorγ y otros usos
BR112012015433A2 (pt) composição farmacêutica substancialmente anidra para aplicação cutânea
CL2021002946A1 (es) Un derivado de tetrahidroisoquinolina sustituido como modulador alostérico positivo de d1
UY32829A (es) Derivados de 3-heteroaril-metil-imidazo-[1,2-b]-pirididazin - 6 -ilo
EA201490166A1 (ru) Фторированные арилалкиламинокарбоксамидные производные
CL2019003720A1 (es) Aplicación de totarol y composición farmacéutica que contiene totarol.
BR112015019307A8 (pt) derivados de ácido butanóico substituído com bisfenila, seus usos, e composição farmacêutica
BR112018070064A2 (pt) composições farmacêuticas estáveis para administração tópica e uso das mesmas
ECSP21027009A (es) Derivados de 4-pirazin-2-ilmetil-morfolina y su uso como medicamento
CO2021014253A2 (es) Formulación de tableta vaginal